By November 11, 2015 Read More →

WHP Completes Cancer Fighting Facility in Record Time

weblogoWHP, one of the UK’s leading cleanroom design, engineering and construction companies, has recently completed TC Biopharm’s (TCB) new clinical manufacturing facility in Glasgow, which processes patients’ own cells in an innovative treatment to target and destroy cancer.

Complies with UK Good Manufacturing Practice (GMP) Regulations
Constructed to comply with stringent UK Good Manufacturing Practice (GMP) regulations, the 3,500sq.ft facility took just 12 weeks to build from start to finish. It includes two cleanrooms, quality control suites and development laboratories designed to support the manufacture of clinical grade product. The facility has just been granted a license to produce human cell therapy products by the Medicines Healthcare Products Regulatory Agency (MHRA).

pic-005WHP’s managing director, Nigel Hall, said: “We have gained a strong reputation for our cleanroom design and construction in the biotechnology industry and it is pleasing to demonstrate our expertise on a project as important as this one – especially so close to home.”

Angela Scott, TCB’s operations director, commented: “The team has done an amazing job building and commissioning our facility in record time. Not only have WHP built an impressive GMP facility in the heart of Scotland, they also ensured that costs were managed in a supportive and proactive manner.

“As TCB’s clinical outreach extends beyond the UK, WHP and TCB will jointly evaluate logistics of facility expansion on a geographical basis, using a combination of modular and mobile clean room systems that can be located in strategic areas to support planned treatment regimes.”

WH Partnership Limited
Staithes 2
The Watermark
Gateshead
Tyne and Wear
NE11 9SN
England

t: +44 (0)191 460 9295

www.wh-partnership.com

Contact This Company

Subject (required)

Name (required)

Company Name (required)

Company Activity (required)

Telephone Number

Your Email (required)

Your Message (required)

[recaptcha recaptcha-174]

Comments are closed.